US-based pharmaceutical conglomerate AbbVie is set to acquire UK rival Shire in a deal worth $54.5 billion, according to reports.
The two were first reported to have entered merger discussions in early May of this year, though no terms had been reached. Now, reports say the agreed-upon details represents 53 percent premium over Shire stock prices.
As part of the takeover, AbbVie agreed to a $1.6 billion breakup fee, say reports. Following the transaction, Shire shareholders will own about one-quarter of the newly combined company.
The deal remains subject to regulatory approval.
Full content: Nasdaq
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Canada’s Agricultural Giants in Antitrust Spotlight
Apr 23, 2024 by
CPI
US House Passes Bill That Could Lead to TikTok Ban
Apr 23, 2024 by
CPI
ADM CFO Resigns Amidst DOJ Investigation Into Accounting Issues
Apr 23, 2024 by
CPI
FTC Throws the Bag: Tapestry’s Capri Deal Blocked Over Market Monopoly Concerns
Apr 22, 2024 by
CPI
Italy’s Antitrust Authority Investigates Enel’s Communication of Energy Price Hikes
Apr 22, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI